Articles tagged with Stem Cell Therapy
Researchers are exploring the potential of generating insulin-producing cells using adult stem cells to treat type 1 diabetes. The partnership aims to restore normal blood sugar levels through autologous cell transplantation, eliminating the need for immunosuppressive agents.
Researchers are exploring optimal dosage and timing for stem cell therapy in adults with strokes and newborns with ischemic injuries. Pilot studies indicate a 25% improvement in recovery, leading to plans for clinical trials within two years.
Researchers found that human mesenchymal stem cells (hMSCs) and bone marrow stromal cells (BMSCs) can migrate to damaged brain tissue after a stroke, improving neural function. The transplanted cells may also enhance tissue repair and functional recovery.
Researchers have made significant progress in cardiac stem cell therapy, exploring novel delivery methods and strategies to improve cell survival. These advancements aim to overcome the challenges of poor vascular supply and inflammation after a heart attack, paving the way for more effective treatments.
UCI researchers have found a novel method to sort stem cells based on their electric charges, which could expedite therapies for conditions like Alzheimer's and Parkinson's diseases. The technique uses electrodes on a tiny glass slide and has the potential to be more cost-effective and quicker than current methods.
Researchers have developed four unique human parthenogenetic stem cell lines that are HLA-homozygous, reducing the risk of provoking an immune reaction. These lines can serve as a renewable source of transplantable cells for treating genetic and degenerative diseases.
A definitive study of 15 randomized trials found that high-dose chemotherapy and autologous stem cell transplantation had no overall survival benefit for women with node-positive breast cancer. However, there was a slight benefit in relapse-free survival.
A recent study by MIT scientists suggests that adult stem cells produced in the brain can only make limited connections, making it challenging to use them for replacement therapy. The research calls into question the potential of using adult stem cells to repair damaged brain tissue and replace lost neurons.
Two studies found a significant increase in five- and ten-year survival rates for MM patients over the past decade, with younger patients showing the most dramatic improvement. Novel therapies have been credited with this trend, particularly among younger patients.
Researchers at Cedars-Sinai Medical Center have developed a novel gene delivery system that can sustain therapeutic expression in the central nervous system for up to 1 year. This innovative approach uses an adenoviral vector called HC-Adv, which is invisible to the immune system and renders previously used vectors ineffective.
Meis1 is required for maintaining leukemia stem cell properties in MLL leukemia, including self-renewal and differentiation arrest. The study provides new insights into the genetic underpinnings of MLL leukemogenesis.
The study found that aging stem cells in fruit flies experienced a decline in growth factor unpaired (upd), leading to reduced stem cell numbers. Artificially increasing upd levels delayed the loss of germline stem cells, suggesting that the niche's molecular signals govern stem cell behavior.
Scientists have discovered a new approach to treat Huntington's disease using stem-cell therapy, which created thousands of new medium spiny neurons in mice. The treatment resulted in improved health and lifespan for the treated mice.
Researchers found that certain cancer treatments can increase the expression of Nanog and BMI1 stem cell markers in cancer cells, allowing them to survive treatment and potentially leading to tumor growth. Understanding these pathways could lead to the development of new therapeutic targets.
Researchers at Children's Hospital of Pittsburgh have identified a unique population of adult stem cells derived from human muscle tissue that can be used to treat muscle injuries and diseases. The myoendothelial cells are easily isolated, proliferate rapidly, and can differentiate into muscle, bone, and cartilage cells.
The HIV/AIDS virus affects adult neural progenitor cells in the brain, preventing them from dividing and contributing to neurodegeneration. The protein gp120 causes both brain injury and prevents its repair, highlighting a potential target for new therapies.
Testicular cancer patients with metastatic disease can be cured with high-dose chemotherapy and a stem cell transplant, as shown in an Indiana University School of Medicine report. The treatment, which involves carboplatin chemotherapy at five times the standard dosage, has a success rate of over 90%.
The Revlimid data presented at ASCO demonstrates a greater one-year survival advantage for patients receiving low dose dexamethasone compared to those receiving the standard high dose of the steroid. In all age ranges, patients benefit from Revlimid with the low dose dexamethasone, showing improved survival rates.
The Friedlander lab will work with six other laboratory groups to conduct pre-clinical work on adult stem cells, aiming to develop a new approach to treating retinal diseases. The therapy targets abnormal blood vessel formation, which is a leading cause of vision loss in Americans.
A recent study published in Cell Stem Cell found that nearly half of couples who underwent in vitro fertilization (IVF) chose to donate their surplus embryos for stem cell research. The key factor was a clear explanation of the options, which helped couples navigate the legal situation and address concerns about donation.
Dr. Evan Snyder's study demonstrates human neural stem cells slow Sandhoff disease progression in mice, offering promise for brain repair therapies for special-needs children. The research lays groundwork for potential therapies for other complex childhood brain disorders.
A Phase 1 trial of mesenchymal stem cells (MSCs) has shown significant improvements in heart function and reduced side effects in patients with acute myocardial infarction (MI). The study, led by Joshua Hare, M.D., found that MSC-treated patients had lower rates of cardiac arrhythmias and improved heart, lung, and global function.
Researchers used human embryonic stem cells to treat a degenerative disease in mice, demonstrating the first successful use of hESCs in a diseased brain. The treatment not only replaced damaged nerve cells but also boosted the brain's supply of an enzyme and reduced inflammation.
Researchers at the University of Pennsylvania have successfully used uniparental embryonic stem cells to repopulate a damaged organ with healthy cells in adult mice. This breakthrough could provide a less controversial alternative to traditional embryonic stem cell therapy, and may offer therapeutic benefits for both males and females.
A sugar molecule called SSEA-4 has been found on the surface of adult stem cells in bone marrow, which give rise to fat, cartilage, and bone. This discovery may help isolate and purify these cells for use in therapies aimed at bone healing, tendon repair, and cartilage regeneration.
Researchers have made breakthroughs in transforming adult stem cells into various tissue types, such as blood vessel cells, nerve-like cells, and muscle-like cells. These advancements hold promise for treating conditions like Parkinson's disease, diabetes, and spinal cord injuries.
Regenerative medicine holds promise for affordable treatments and offsetting donor shortages, particularly for diabetes, heart disease, and infectious diseases. The study prioritizes 10 applications, including novel insulin replacement methods, regenerating failed heart muscle, and engineered immune cells.
The Tri-Institutional Stem Cell Initiative has approved $6.7 million in funding for 17 stem cell research projects, exploring basic biology and therapeutic potential of human and model organism-derived stem cells. The grants support collaborative research across three institutions, including Memorial Sloan-Kettering Cancer Center.
Researchers developed an effective treatment using embryonic stem cells to restore motor function in paralyzed rats. GDNF was found to be a focal attractive cue for transplanted axons, facilitating the establishment of neuromuscular junctions and resulting in noticeable recovery.
The study found that the average time to disease progression was approximately eight months for patients taking dexamethasone alone, while those on the Thal/Dex regimen had an average progression time exceeding 17 months. Researchers also reported more frequent side effects with the combination therapy.
Researchers found that rituximab reduced the severity of chronic GVHD in 70% of study participants, with nearly three-fourths experiencing complete remissions. The therapy also enabled patients to reduce corticosteroid use by over 50%.
Researchers have discovered two new sources of stem cells with high cardiomyogenic potential, derived from menstrual blood and umbilical cord blood. These findings suggest that these cells may be able to repair or replace damaged cardiac muscle, offering a promising treatment option for heart dysfunctions.
A recent study found that stem cell mobilization therapy does not improve left ventricular recovery in patients with acute myocardial infarction. Despite significant mobilization of bone marrow stem cells, treatment did not alter infarct size or risk of restenosis or major adverse cardiac events.
A radical proposal suggests that California's CIRM could accelerate the development of stem cell therapies by implementing a patent pool and a shared prize system. This approach aims to stimulate innovation, make treatments more affordable, and establish a new medical innovation model for the 21st century.
The sympathetic nervous system plays a crucial role in regulating hematopoietic stem cell mobilization. Researchers found that defects in the transmission of signals via this system can stall stem cell movement. Drugs that stimulate the sympathetic nervous system restored stem cell movement in mice with impaired ability to respond to n...
Cedars-Sinai researchers have developed a new delivery system that can effectively regulate therapeutic gene expression, overcoming obstacles in bringing genetic therapies to humans. The system allows for the flexibility to turn gene expression on or off, even in the presence of an immune response, making it a critical tool for treatin...
Researchers estimated that 150 blood group compatible donors, 100 O donors, or ten highly selected donors could provide maximum benefit for HLA matching. The study aims to establish a hESC bank with sufficient HLA diversity for the UK population.
The NHLBI-funded program aims to translate knowledge into clinical practice for treating heart, lung, and blood diseases. It focuses on repairing damaged heart muscle, reducing immune complications, and enhancing adult stem cell interactions.
A new study reveals how the GDF11 protein controls retinal-cell differentiation during development, making it an attractive therapeutic target. By manipulating this process, researchers may be able to harness the power of existing stem cells in the retina to replace damaged or diseased cells and potentially cure visual disorders.
Researchers at UCI identified a protein called prokineticin 2 (PK2) that directs new neurons created from adult stem cells to specific brain regions. This discovery could lead to targeted therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as stroke and other brain injuries.
Researchers used SPECT imaging to evaluate the effectiveness of stem cell therapy in patients with coronary heart disease. The study found that stem cells improved damaged heart function, surpassing improvements from increased blood flow to the affected area.
A study of 11 patients with non-Hodgkin's lymphoma who have failed standard chemotherapy found that Zevalin was effective in inducing partial and complete responses in three patients. The treatment was well-tolerated, with side effects including thrombocytopenia and neutropenia.
Researchers at UCLA's new $20 million Institute for Stem Cell Biology and Medicine are exploring various approaches to combat HIV, cancer and neurological disorders. The institution aims to harness the power of embryonic and adult stem cells to develop revolutionary new treatments.
Researchers from the Forsyth Institute and University of Texas Health Science Center at San Antonio describe successful experiments in bioengineering mineralized tissues, including periodontal tissues and replacement tooth phenotypes. This breakthrough is supported by the National Institute of Dental and Craniofacial Research.
Researchers have developed a new way to culture human embryonic stem cells without using animal-derived materials, reducing the risk of contamination with pathogens. This breakthrough could lead to safer and more effective stem cell therapies for treating various diseases.
The level of signal-joint TRECs (sjTRECs) in the blood appears to directly reflect the ability of the transplant recipient's thymus gland to process donated stem cells. High levels of sjTRECs indicate a successful reconstitution of the T cell population, improving patient outcomes.
A new study has provided proof of principle for a combined stem cell-gene therapy approach as a potential treatment for cystic fibrosis. The researchers were able to correct the CFTR gene defect using adult stem cells and ex vivo gene therapy, which may offer advantages in screening and long-term function.
Researchers transplanted BM-SP stem cells into mice with cardiomyopathy, but found that only 2 muscle fibers expressed restored sarcoglycan levels. The study suggests alternative approaches should be investigated for regenerative medicine.
Researchers identified a complete deficiency in the CD3 epsilon chain of the T cell receptor causing SCID, leading to normal B cells but no T cells. Early diagnosis via bone marrow stem cell transplantation can result in a survival rate as high as 97% for patients with this mutation.
Researchers at Mayo Clinic demonstrate the potential of embryonic stem cells to rebuild damaged heart tissue, improving contractile function and ventricular remodeling. The study found that stem cell-derived cardiomyocytes integrated into infarcted areas without adverse effects.
Researchers at the NIH will conduct a clinical study to assess the safety and efficacy of hematopoietic stem cell transplantation in treating severe forms of lupus. The study aims to create a new immune system that doesn't attack healthy cells, offering hope for patients with limited treatment options.
The Oregon Stem Cell Center aims to develop therapies using adult stem cells for human diseases through a rapid approach from basic research to animal trials and human studies. The center's focus will be on the liver and pancreas, building on OHSU's existing expertise in cell therapy.
Researchers at Johns Hopkins Medicine discovered a rare stem cell in multiple myeloma that gives rise to malignant bone marrow plasma cells. Current treatments may not be effective against this errant stem cell, leading scientists to explore dual-therapy approaches to target both the visible and root causes of the disease.
The University of Minnesota has been awarded a major NIH contract to bring new cellular therapies to human clinical trials. The project will focus on developing biological therapies using adult stem cells, umbilical cord blood, tumor vaccines, and genetically modified immune system cells.
Researchers found that intravenous infusions of human umbilical cord blood stem cells delayed ALS disease progression by at least two to three weeks and improved survival in mice. The cells also circulated to organs outside the central nervous system, suggesting an immune-protective mechanism.
Researchers have developed a method to extend the shelf life of cultured fetal neural stem cells, enabling the generation of enough cells to treat diseases like Parkinson's and ALS. The study characterized long-term neural stem cell lines using gene chip analysis, which may help create customized cells for therapy.
Researchers at Stanford Medicine have successfully isolated a key protein that helps maintain the youthful state of hematopoietic stem cells. The discovery, led by Irving Weissman and Roeland Nusse, reveals how this protein, Wnt, triggers stem cell division and expansion.
Researchers found that thalidomide therapy works for approximately one year on average, with benefits not being transient. The study's findings offer significant hope for improved survival rates in multiple myeloma patients, an incurable cancer.
Researchers at Johns Hopkins Lupus Center and Kimmel Cancer Center found that high-dose intravenous cyclophosphamide can lead to complete responses and partial responses in lupus patients who failed standard therapy. The treatment also had fewer side effects compared to traditional treatments.
Researchers are exploring a new stem cell therapy, called therapeutic angiogenesis, to grow new blood vessels in damaged heart muscle. The treatment, which uses cord blood stem cells, aims to improve outcomes for people with severe coronary artery disease and congestive heart failure.